العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
EspañolGLUCOSE-6-PHOSPHATE DEHYDROGENASE
(Redirected from G6PD)
'Glucose-6-phosphate dehydrogenase' ('G6PD') is an enzyme in the pentose phosphate pathway (see image), a metabolic pathway that supplies reducing energy to cells (most notably erythrocytes) by maintaining the level of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH).
The NADPH in turn maintains the level of glutathione in these cells that helps protect the red blood cells against oxidative damage.
Its deficiency is often a common problem, and can be offset by a simple infection, ingestion of fava beans, or reaction with medicines, AAA, antibiotics, antipyretics, and antimalarials.
G6PD converts glucose-6-phosphate into 6-phosphoglucono-δ-lactone and is the rate-limiting enzyme of the ''pentose phosphate pathway''.
G6PD deficiency causes a problem in patients who receive the drugs dapsone, sulfamethoxazole, or primaquine. G6PD deficient patients who are treated with these agents are more likely to experience the toxicity known as hemolytic anemia.
★ Glucose-6-phosphate dehydrogenase deficiency
★
'Glucose-6-phosphate dehydrogenase' ('G6PD') is an enzyme in the pentose phosphate pathway (see image), a metabolic pathway that supplies reducing energy to cells (most notably erythrocytes) by maintaining the level of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH).
The NADPH in turn maintains the level of glutathione in these cells that helps protect the red blood cells against oxidative damage.
Its deficiency is often a common problem, and can be offset by a simple infection, ingestion of fava beans, or reaction with medicines, AAA, antibiotics, antipyretics, and antimalarials.
G6PD converts glucose-6-phosphate into 6-phosphoglucono-δ-lactone and is the rate-limiting enzyme of the ''pentose phosphate pathway''.
| Contents |
| Clinical Significance |
| See also |
| External links |
Clinical Significance
G6PD deficiency causes a problem in patients who receive the drugs dapsone, sulfamethoxazole, or primaquine. G6PD deficient patients who are treated with these agents are more likely to experience the toxicity known as hemolytic anemia.
See also
★ Glucose-6-phosphate dehydrogenase deficiency
External links
★
This article provided by Wikipedia. To edit the contents of this article, click here for original source.
psst.. try this: add to faves
